Exciting news! CEDAR is a collaborator on the new #REFINEstudy.
This @ResearchWales funded pilot trial explores if rapid viral testing (RSV, COVID, Flu) for febrile infants in EDs can reduce invasive procedures & antibiotic use. Our team will be interviewing parent/caregivers and clinicians to understand the acceptability of the POC test.
We're proud to collaborate with @CTRCardiffUni, @CV_UHB & other partners on this vital Welsh-led research to improve infant care.
Read more about the study: cardiff.ac.uk/centre-for-tri…@Dr_JoanneEuden@jordan_evans98#Paediatrics#QualitativeResearch#POCtesting
🇵🇱 New Study from IFA Poland Board Member: Early AKI Detection in EVAR Patients 🧬
🔬 A new publication by Dr. Konrad Zuzda, board member of the IFA Poland Chapter, highlights the use of proenkephalin A 119–159 (penKid) as an early biomarker for acute kidney injury (AKI) in patients undergoing endovascular aortic repair (EVAR).
🧪 Key Findings:
📈 80% sensitivity for AKI detection on post-op day 1
🏥 AKI patients had longer hospital stays (12 vs 9 days)
📉 Lower 6-month survival in the AKI group
🩺 Point-of-care (POC) testing outperformed standard lab methods
💡 Why it matters: AKI is often diagnosed too late. This bedside biomarker may allow earlier detection and intervention, particularly useful for ruling out high-risk patients thanks to its 93% negative predictive value.
📜 Walczak-Wieteska P., Zuzda K., Małyszko J. et al.
Proenkephalin A 119–159 as an early biomarker of acute kidney injury in complex endovascular aortic repair
Perioper Med (2025) 14:66
🔗 perioperativemedicinejournal…#AKI#penKid#EVAR#VascularSurgery#Biomarkers#ICU#POCtesting#CriticalCare#IFAPoland#Anesthesiology
Blood Gas controls will never be the same again!
No glass shards or possible cut fingers. Fifteen-minute open vial stability time.
Curious? Need to know more? Contact our Product Specialist team at 502-501-1180 ext 1.
#bloodgas#POCtesting#cliaregulations#respiratorycare
🌟During the Hospital Expo, Biotime had the pleasure of engaging with healthcare providers, laboratory managers, and decision-makers who were intrigued by the potential of our POCT product line.
Let's shape the future of healthcare together! 🌍💙
#HospitalExpo#POCTesting
CueSee®VeriSTAT LVM and CueSee®VeriSTAT QC are now available in our CueSee®Compare program! Contact our Customer Service team with any questions or to schedule a quick tutorial with your Product Specialist.
#qualitycontrol#bloodgascontrols#QCmanagement#QCreports#POCtesting
Our partners at @AdventistHealth like Dr. Candace Westgate, DO, and Denise Gruezensky, RN, MSN, FNP are expanding access to genetic services for tens of thousands of patients through #POCTesting. Proud to see their research represented! (2/4) #COHGenomics23#GeneChat
In 2021 the UKHSA introduced new criteria for manufacturers seeking to place their #COVID19 tests on the UK market (#CTDA). Today we can inform you that our PROmate® COVID-19 2G direct to PCR assay has been approved: bit.ly/3rRALEi#Novacyt#NCYT#ALNOV#COVID19